ZD241115C55000
- 0.50
- 0.000.00%
Ziff Davis Newsroom
Ziff Davis to Participate in One Investor Conference in November
Health ECareers and the Pediatric Infectious Diseases Society Announce Partnership
Press Release: Ziff Davis to Announce Third Quarter 2024 Earnings
Ziff Davis Inc (ZD) Q2 2024 Earnings Call Highlights: Strategic Acquisitions and AI Integration ...
23% Earnings Growth Over 3 Years Has Not Materialized Into Gains for Ziff Davis (NASDAQ:ZD) Shareholders Over That Period
Ziff Davis (NASDAQ:ZD) Seems To Use Debt Quite Sensibly
Ziff Davis Completes One Acquisition in Q3 2024
VIPRE Introduces All-in-one Endpoint EDR+MDR Package to Help Deliver Around-the-clock Managed Security
Is Ziff Davis, Inc. (ZD) the Worst Marketing Stock to Buy?
Spiceworks Announces the 17th Annual SpiceWorld Conference: The Ultimate IT Pro and Vendor Gathering, November 13-14, 2024
New Study From Health ECareers Finds Women in Healthcare Satisfied With Their Jobs, but See Obstacles to Progress
Castle Connolly Releases 2024 Castle Connolly Top Hispanic & Latino Doctors
Is Ziff Davis, Inc.'s (NASDAQ:ZD) Stock Price Struggling As A Result Of Its Mixed Financials?
DeepIntent and Everyday Health Group Partner to Offer Exclusive Access to Premium Health Segments and Advanced Targeting
CNH Industrial, Parsons and More Join S&P MidCap 400
Where Ziff Davis Stands With Analysts
Ziff Davis Price Target Maintained With a $95.00/Share by RBC Capital
RBC Capital Maintains Ziff Davis(ZD.US) With Buy Rating, Maintains Target Price $95
RBC Capital analyst Rishi Jaluria maintains $Ziff Davis(ZD.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 49.2% and a
RBC Capital Sticks to Their Buy Rating for Ziff Davis, Inc. (ZD)
Positive Earnings Growth Hasn't Been Enough to Get Ziff Davis (NASDAQ:ZD) Shareholders a Favorable Return Over the Last Three Years